Abstrait

Prostate Cancer Cell Lines Treated with Hydralazine and Panobinostat have less Malignant properties

Anette Jacobs

Prostate Cancer (PCa) is the second most frequent malignancy in males and the fifth leading cause of death from cancer worldwide. More than 80% of PCa cases are now identified as localised illnesses, but up to a third of these individuals will experience recurrence and progression in the future. Androgen Deprivation Therapy (ADT) is the most prevalent treatment for advanced PCa because androgens and Androgen Receptor (AR) signalling are so important in normal prostate development and PCa progression. Despite an early response to ADT, patients usually become resistant and progress to Castration- Resistant Prostate Cancer (CRPC) between 12 months and 30 months. Despite the fact that next-generation androgen signalling inhibitors have improved the prognosis, these patients still lack curative drugs, necessitating the urgent development of novel therapeutic approaches.